Literature DB >> 32063704

Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.

Yanli Peng1,2, Lianhua Zhu1, Luofu Wang3, Yu Liu1, Kejing Fang1, Minmin Lan1,2, Daijia Shen1, Deng Liu1, Zhiping Yu3, Yanli Guo1.   

Abstract

PURPOSE: To construct nanobubbles (PTX-AMD070 NBs) for targeted delivery of paclitaxel (PTX) and AMD070, examine their performance in ultrasound molecular imaging of breast cancer and cervical cancer and their therapeutic effect combined with ultrasound targeted nanobubble destruction (UTND).
MATERIALS AND METHODS: PTX-AMD070 NBs were prepared via an amide reaction, and the particle size, zeta potential, encapsulation rate and drug loading efficiency were examined. Laser confocal microscopy and flow cytometry were used to analyze the targeted binding ability of PTX-AMD070 NBs to CXCR4+ MCF-7 cells and C33a cells. The effect of PTX-AMD070 NBs combined with UTND on cell proliferation inhibition and apoptosis induction was detected by CCK-8 assays and flow cytometry. The contrast-enhanced imaging features of PTX-AMD070 NBs and paclitaxel-loaded nanobubbles were compared in xenograft tumors. The penetration ability of PTX-AMD070 NBs in xenograft tissues was evaluated by immunofluorescence. The therapeutic effect of PTX-AMD070 NBs combined with UTND on xenograft tumors was assessed.
RESULTS: PTX-AMD070 NBs showed a particle size of 494.3±61.2 nm, a zeta potential of -22.4±1.75 mV, an encapsulation rate with PTX of 53.73±7.87%, and a drug loading efficiency with PTX of 4.48±0.66%. PTX-AMD070 NBs displayed significantly higher targeted binding to MCF-7 cells and C33a cells than that of PTX NBs (P<0.05), and combined with UTND manifested a more pronounced effect in inhibiting cell proliferation and promoting apoptosis than other treatments. PTX-AMD070 NBs aggregated specifically in xenograft tumors in vivo, and significantly improved the image quality. Compared with other treatment groups, PTX-AMD070 NBs combined with UTND exhibited the smallest tumor volume and weight, and the highest degree of apoptosis and necrosis.
CONCLUSION: PTX-AMD070 NBs improved the ultrasound imaging effect in CXCR4+ xenograft tumors and facilitated targeted therapy combined with UTND. Therefore, this study provides an effective method for the integration of ultrasound molecular imaging and targeted therapy of malignant tumors.
© 2019 Peng et al.

Entities:  

Keywords:  AMD070; malignant tumor; nanobubbles; paclitaxel; ultrasound imaging

Mesh:

Substances:

Year:  2019        PMID: 32063704      PMCID: PMC6885000          DOI: 10.2147/IJN.S210478

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  40 in total

1.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Authors:  Kohei Shitara; Mustafa Özgüroğlu; Yung-Jue Bang; Maria Di Bartolomeo; Mario Mandalà; Min-Hee Ryu; Lorenzo Fornaro; Tomasz Olesiński; Christian Caglevic; Hyun C Chung; Kei Muro; Eray Goekkurt; Wasat Mansoor; Raymond S McDermott; Einat Shacham-Shmueli; Xinqun Chen; Carlos Mayo; S Peter Kang; Atsushi Ohtsu; Charles S Fuchs
Journal:  Lancet       Date:  2018-06-04       Impact factor: 79.321

2.  Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Authors:  Annemieke Cats; Edwin P M Jansen; Nicole C T van Grieken; Karolina Sikorska; Pehr Lind; Marianne Nordsmark; Elma Meershoek-Klein Kranenbarg; Henk Boot; Anouk K Trip; H A Maurits Swellengrebel; Hanneke W M van Laarhoven; Hein Putter; Johanna W van Sandick; Mark I van Berge Henegouwen; Henk H Hartgrink; Harm van Tinteren; Cornelis J H van de Velde; Marcel Verheij
Journal:  Lancet Oncol       Date:  2018-04-09       Impact factor: 41.316

3.  How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.

Authors:  Josep M Borras; Yolande Lievens; Michael Barton; Julieta Corral; Jacques Ferlay; Freddie Bray; Cai Grau
Journal:  Radiother Oncol       Date:  2016-02-24       Impact factor: 6.280

Review 4.  Ultrasound-based triggered drug delivery to tumors.

Authors:  Ankit Jain; Ankita Tiwari; Amit Verma; Sanjay K Jain
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 5.  Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.

Authors:  Yinan Zhong; Fenghua Meng; Chao Deng; Zhiyuan Zhong
Journal:  Biomacromolecules       Date:  2014-05-12       Impact factor: 6.988

6.  Formation of CoS2 Nanobubble Hollow Prisms for Highly Reversible Lithium Storage.

Authors:  Le Yu; Jing Fan Yang; Xiong Wen David Lou
Journal:  Angew Chem Int Ed Engl       Date:  2016-08-16       Impact factor: 15.336

7.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

8.  Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells.

Authors:  Daisuke Uchida; Nobuyuki Kuribayashi; Makoto Kinouchi; Yuta Sawatani; Michiko Shimura; Toshimitsu Mori; Tomonori Hasegawa; Youji Miyamoto; Hitoshi Kawamata
Journal:  Oncol Rep       Date:  2018-04-25       Impact factor: 3.906

9.  In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Authors:  Kathrin Philipp-Abbrederis; Ken Herrmann; Stefan Knop; Margret Schottelius; Matthias Eiber; Katharina Lückerath; Elke Pietschmann; Stefan Habringer; Carlos Gerngroß; Katharina Franke; Martina Rudelius; Andreas Schirbel; Constantin Lapa; Kristina Schwamborn; Sabine Steidle; Elena Hartmann; Andreas Rosenwald; Saskia Kropf; Ambros J Beer; Christian Peschel; Hermann Einsele; Andreas K Buck; Markus Schwaiger; Katharina Götze; Hans-Jürgen Wester; Ulrich Keller
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

10.  Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.

Authors:  Mamoru Morimoto; Yoichi Matsuo; Shuji Koide; Ken Tsuboi; Tomoya Shamoto; Takafumi Sato; Kenta Saito; Hiroki Takahashi; Hiromitsu Takeyama
Journal:  BMC Cancer       Date:  2016-05-12       Impact factor: 4.430

View more
  4 in total

1.  Nested Nanobubbles for Ultrasound-Triggered Drug Release.

Authors:  Damien V B Batchelor; Radwa H Abou-Saleh; P Louise Coletta; James R McLaughlan; Sally A Peyman; Stephen D Evans
Journal:  ACS Appl Mater Interfaces       Date:  2020-06-19       Impact factor: 9.229

Review 2.  Nanosized Contrast Agents in Ultrasound Molecular Imaging.

Authors:  Fengyi Zeng; Meng Du; Zhiyi Chen
Journal:  Front Bioeng Biotechnol       Date:  2021-11-29

3.  Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy.

Authors:  Jianjun Hu; Jiangyi He; Yunlong Wang; Yang Zhao; Kejing Fang; Yan Dong; Yanrong Chen; Yue Zhang; Chi Zhang; Hongwei Wang; Jun Tan; Junyi Wang; Ruiyang Zi; Chengxiang Liu; Houjie Liang; Yanli Guo; Juanjuan Ou
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

Review 4.  Ultrasound and Nanomedicine for Cancer-Targeted Drug Delivery: Screening, Cellular Mechanisms and Therapeutic Opportunities.

Authors:  Chien-Hsiu Li; Yu-Chan Chang; Michael Hsiao; Ming-Hsien Chan
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.